For someone with obesity and painful knee osteoarthritis, improvement in mobility may matter more than a percentage on a scale. STEP 9 examined that clinical setting directly. Its findings support a focused discussion about pain and function, while leaving structural joint-repair claims outside the reported result.
What the trial measured
STEP 9 enrolled 407 participants with obesity, clinically and radiologically diagnosed moderate knee osteoarthritis, and at least moderate pain. Over 68 weeks, the WOMAC pain score improved by 41.7 points with semaglutide and 27.5 with placebo. Participants also received diet and activity counseling. These are findings from the primary trial publication.
The WOMAC pain scale used in the study ranges from 0 to 100, with higher scores indicating worse pain. A reduction is therefore an improvement. The between-group contrast should be distinguished from the change observed within either group.
Do not rename the endpoint
The paper’s principal outcomes concerned weight and pain, with physical function also assessed. A favorable pain result does not demonstrate regrowth of cartilage, reversal of radiographic disease or avoidance of every future operation.
Those additional claims require their own endpoints and follow-up. A citation to STEP 9 is relevant to the studied outcomes, not a general license to describe semaglutide as a regenerative knee treatment.
Match the person to the clinical question
The participants had obesity and a specified osteoarthritis diagnosis. The study does not describe every source of knee pain or establish a treatment approach for someone whose symptoms have not been evaluated.
A useful consultation can separate the diagnosis, the desired functional improvement and the role of weight-related care. Bring the activities limited by pain and the existing management plan rather than starting with a demand for one medicine.
Keep benefit and tolerability together
Adverse events leading to permanent treatment discontinuation occurred in 6.7% of the semaglutide group and 3.0% with placebo, most often because of gastrointestinal disorders. The trial report therefore supports discussing practical treatment experience alongside the pain finding.
The study used a defined injectable intervention; it does not validate a compounded preparation or an unrelated oral formulation. Nor does it instruct readers to replace existing joint care independently.
STEP 9 is most useful when its specific contribution remains clear: better average pain and physical-function outcomes in a selected obesity-and-knee-osteoarthritis population, rather than proof that a damaged joint was rebuilt.
Sources and reading scope
Research draft prepared November 7, 2026. This is educational synthesis, not medical review or an individualized treatment recommendation. Check the linked original records and current labels before making a decision.